Supernus Pharmaceuticals Engages with Investors
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), a biopharmaceutical company dedicated to developing treatments for central nervous system (CNS) diseases, has made exciting advancements in its journey. The company has announced its involvement in several investor conferences scheduled for September, affording investors the chance to gain insight into its operational objectives and product developments.
Upcoming Investor Conferences
Supernus Pharmaceuticals will partake in a series of key investor conferences. These events will provide an excellent platform for management to share insights and engage with investors.
Cantor Global Healthcare Conference
This prominent conference will take place on Wednesday, September 3, 2025, at 8:00 a.m. ET. Supernus management will be available to discuss the company’s strategic initiatives and growth prospects. The event will be held at the New York Marriott Marquis in New York City.
Wells Fargo Healthcare Conference
Following closely, the Wells Fargo Healthcare Conference is set for Thursday, September 4, 2025, at 8:45 a.m. ET. Held at Encore Boston Harbor in Everett, Massachusetts, this conference will also serve as a valuable opportunity for Supernus to engage with its stakeholders.
TD Cowen's 5th Annual Summit
On Thursday, September 18, 2025, Supernus will participate in the virtual TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit. The management will be involved in a fireside chat at 10:40 a.m. ET, discussing innovative approaches and future directions in treating CNS disorders.
Engaging with Investors
Investors interested in meeting with Supernus Pharmaceuticals' management during these conferences are encouraged to reach out to the respective conference coordinators. This is a pivotal moment for the company, as it seeks to strengthen relationships and provide transparency regarding its business strategies.
Accessing Live Presentations
For those unable to attend in person, Supernus Pharmaceuticals will offer live audio webcasts of these presentations. Interested parties can access the webcasts in the Events & Presentations section of the Supernus Pharmaceuticals website. The webcasts will be archived for 60 days, allowing wider access after the events conclude.
About Supernus Pharmaceuticals
Supernus Pharmaceuticals is at the forefront of developing new therapies for CNS diseases. With a diverse portfolio, the company has developed treatments for various conditions including attention-deficit hyperactivity disorder (ADHD), Parkinson’s disease (PD), epilepsy, migraine, and more. Their dedication to advancing innovative CNS treatments underscores their commitment to improving patient outcomes.
The portfolio also includes promising drug candidates aimed at treating conditions such as depression and epilepsy, reflecting the company’s mission to address significant unmet medical needs in the CNS arena.
Contact Information
For further inquiries or to arrange a meeting, please contact:
Jack A. Khattar, President and CEO
Timothy C. Dec, Senior Vice President and CFO
Supernus Pharmaceuticals, Inc.
(301) 838-2591
Investor Contact:
Peter Vozzo
ICR Healthcare
(443) 213-0505
peter.vozzo@icrhealthcare.com
Frequently Asked Questions
What is Supernus Pharmaceuticals known for?
Supernus Pharmaceuticals specializes in developing products for the treatment of central nervous system (CNS) diseases, including ADHD and epilepsy.
When are the upcoming investor conferences?
Supernus will participate in investor conferences on September 3, 4, and 18, 2025.
How can investors access the live webcasts?
Investors can access live audio webcasts through the Events & Presentations section on the Supernus Pharmaceuticals website.
Who should I contact for more information about meetings?
Interested parties should contact the conference coordinators for the respective events to arrange meetings.
What types of conditions does Supernus focus on?
Supernus focuses on treating CNS disorders, including ADHD, dyskinesia in Parkinson's disease, and epilepsy, among others.
